BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Quentmeier, Hilmar ^a   Eberth, Sonja ^a   Romani, Julia ^a   Zaborski, Margarete ^a   Drexler, Hans G ^a  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; BCR ABL PROTEIN; DASATINIB; IMATINIB; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN S6; RAPAMYCIN; STAT5 PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MUTATION; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 79551629888     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-6     Document Type: Article

References (38)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652. (Pubitemid 34815868)
2. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042. (Pubitemid 32267973)
3. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001, 293:876-880.
4. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, Preudhomme C: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018. (Pubitemid 34832631)
5. Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739-3745. (Pubitemid 39564452)
6. Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96:1070-1079. (Pubitemid 30616875)
7. Weisberg E, Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000, 95:3498-3505. (Pubitemid 30428483)
8. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000, 95:1758-1766.
9. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, van Etten RA, Li S: Requirement of Src kinases Lyn, Hck and Fgr for BCRABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics 2004, 36:453-461.
10. Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM: Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008, 68:9809-9816.
11. Thomas EK, Cancelas JA, Zheng Y, Williams DA: Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia 2008, 22:894-904.
12. Deininger MWN, Goldman JM, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997, 90:3691-3698. (Pubitemid 27473440)
13. Breccia M, Alimena G: Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leukemia Res 2010, 34:129-132.
14. Dovat S, Payne KJ: Tumor suppression in T cell leukemia - the role of Ikaros. Leukemia Res 2010, 34:416-417.
15. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453:110-114. (Pubitemid 351630327)
16. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foà R, Marinelli G: Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell' Adulto Acute Leukemia Working Paty (GIMEMA AL WP). Blood 2009, 114:2159-2167.
17. Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, Soverini S, Amabile M, Poerio A, Saglio G, Pane F, Berton G, Baruzzi A, Vitale A, Charetti S, Perini G, Foa R, Baccrani M, Martinelli G: Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2009, 112:3847-3855.
18. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Joergensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009, 23:1999-2006.
19. Deininger M: Src kinases in Ph+ lymphoblastic leukemia. Nature Genetics 2004, 36:440-441.
20. Li S: Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008, 49:19-26.
21. Kolch W, Pitt A: Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer 2010, 10:618-629.
22. Ilaria RL, Van Etten RA: P210 and P190BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271:31704-31710.
23. Kharas MG, Fruman DA: ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005, 65:2047-2053. (Pubitemid 40490106)
24. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller- Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A: Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005, 19:1774-1782. (Pubitemid 41486155)
25. Guertin DA, Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med 2005, 11:353-361. (Pubitemid 41080576)
26. Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P: Identification of mTOR as a novel bifunctional target in chronic myeloid leukema: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J 2005, 19:960-962. (Pubitemid 40827717)
27. Sillaber C, Mayerhofer M, Böhm A, Vales A, Gruze A, Aichberger KJ, Esterbauer H, Pfeilstöcker M, Sperr WR, Pickl WF, Haas OA, Valent P: Evaluation of antileukaemic effects of rapamycin in patients with imatinib resistant chronic myeloid leukaemia. Eur J Clin Inv 2008, 38:43-52. (Pubitemid 350293855)
28. Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S: A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33 MM myeloma model. Cancer Res 2008, 68:5519-5523.
29. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, Zhao Z, Huber HE, Jones RE: Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005, 4:271-279. (Pubitemid 40340206)
30. Karnoub AE, Weinberg RA: Ras oncogenes: split personalities. Nature Rev Mol Cell Biol 2008, 9:517-531. (Pubitemid 351881844)
31. Kales SC, Ryan PE, Nau MM, Lipkowitz S: Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res 2010, 70:4789-4794.
32. Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K: CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/ myelodysplastic syndrome subtypes. Clin Cancer Res 2009, 15:2238-2247.
33. Horn S, Bergholz U, Jücker M, McCubrey JA, Trümper L, Srocking C, Bäsecke J: Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene 2008, 27:4096-4106. (Pubitemid 351931986)
34. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554. (Pubitemid 38541907)
35. Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. Braunschweig , 2 2010.
36. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NCP, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196. (Pubitemid 35331833)
37. Uphoff CC, Habig S, Fombonne S, Matsuo Y, Drexler HG: ABL-BCR expression in BCR-ABL-positive human leukemia cell lines. Leukemia Res 1999, 23:1055-1060. (Pubitemid 29488653)
38. Quentmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, MacLeod RAF, Drexler HG: SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol 2009, 2:3.